摘要 |
The present invention relates to a Bacillus amyloliquefaciens K317 strain suppressing the growth of antibiotics-resistant pathogenic microorganisms or enteropathogenic microorganisms, more precisely a Bacillus amyloliquefaciens K317 strain, a culture supernatant thereof and an antibacterial metabolite separated from the same. The Bacillus amyloliquefaciens K317 strain, the culture supernatant thereof and the antibacterial metabolite separated from the same of the invention can be effectively used for the composition, health food, and probiotics for inhibiting the growth of antibiotics-resistant pathogenic microorganisms and enteropathogenic microorganisms, since they have excellent antibacterial activity and inhibition effect on the growth of methicillin resistant pathogenic microorganism and such enteropathogenic microorganism as Edwardsiella tarda, E. coli and Staphylococcus epidermidis. |
主权项 |
1. A pharmaceutical formulation comprising:
a) one or more suitable excipients selected from the group consisting of: i) starch, calcium carbonate, sucrose, lactose, gelatin, or combinations thereof, ii) water, liquid paraffin, wetting agents, sweeteners, aromatics, preservatives, or combinations thereof and iii) propylene glycol, polyethylene glycol, vegetable oil, an injectable ester, polyoxyethylene (4) sorbitan monostearate, cacao butter, laurin butter, glycerol, gelatin, or combinations thereof; and b) an isolated Bacillus amyloliquefaciens K317 strain, a culture containing Bacillus amylofiquefaciens K317 strain or a culture supernatant containing a Bacillus amylofiquefaciens K317 strain, able to inhibit the growth of antibiotics-resistant pathogenic microorganisms or enteropathogenic microorganisms, wherein said strain is deposited at Korean Collection for Type Cultures under Accession No. KCTC 11042BP, wherein said pharmaceutical formulation is in a form selected from a pill, a tablet, a capsule or an emulsion. |